A Phase I/II Trial of ABI-008 (Nab-Docetaxel) in Patients With Hormone-Refractory Prostate Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 16 Sep 2015
At a glance
- Drugs Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- 10 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jun 2011 Celgene Corporation as company and lead trial centre added as reported by ClinicalTrials.gov.
- 09 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.